a b/processing/MACCROBAT/19860007.ann
1
T1  Age 2 13    70-year-old
2
T2  Sex 14 17   man
3
T3  Clinical_event 22 30    referred
4
E1  Clinical_event:T3 
5
T4  Nonbiological_location 38 46    hospital
6
T5  Biological_structure 51 58  gastric
7
T6  Disease_disorder 59 65  cancer
8
E2  Disease_disorder:T6 
9
R1  MODIFY Arg1:T5 Arg2:E2  
10
T7  Diagnostic_procedure 104 130    esophagogastroduodenoscopy
11
E3  Diagnostic_procedure:T7 
12
T8  Diagnostic_procedure 131 136    (EGD)
13
E4  Diagnostic_procedure:T8 
14
R2  IDENTICAL Arg1:E4 Arg2:E3   
15
T9  History 138 168 No significant medical history
16
T10 Sign_symptom 192 199    dysuria
17
E5  Sign_symptom:T10 
18
T11 Detailed_description 200 229    caused by bladder contraction
19
R3  MODIFY Arg1:T11 Arg2:E5 
20
T12 Diagnostic_procedure 239 249    laboratory
21
E6  Diagnostic_procedure:T12 
22
T13 Diagnostic_procedure 264 282    serum level of AFP
23
E7  Diagnostic_procedure:T13 
24
T14 Lab_value 286 296   32.3 ng/mL
25
R4  MODIFY Arg1:T14 Arg2:E7 
26
R5  SUB_PROCEDURE Arg1:E7 Arg2:E6   
27
T15 Diagnostic_procedure 396 420    carcinoembryonic antigen
28
E8  Diagnostic_procedure:T15 
29
T16 Diagnostic_procedure 421 426    (CEA)
30
E9  Diagnostic_procedure:T16 
31
T17 Diagnostic_procedure 431 456    carbohydrate antigen 19-9
32
E10 Diagnostic_procedure:T17 
33
T18 Diagnostic_procedure 457 465    (CA19-9)
34
E11 Diagnostic_procedure:T18 
35
R6  IDENTICAL Arg1:E11 Arg2:E10 
36
R7  IDENTICAL Arg1:E9 Arg2:E8   
37
R8  SUB_PROCEDURE Arg1:E8 Arg2:E6   
38
R9  SUB_PROCEDURE Arg1:E10 Arg2:E6  
39
T19 Lab_value 329 349   no other abnormality
40
R10 MODIFY Arg1:T19 Arg2:E8 
41
R11 MODIFY Arg1:T19 Arg2:E10    
42
T20 Coreference 467 470 EGD
43
E12 Coreference:T20 
44
R12 IDENTICAL Arg1:E12 Arg2:E3  
45
T21 Sign_symptom 503 507    mass
46
E13 Sign_symptom:T21 
47
T22 Detailed_description 487 502    ulcerofungating
48
R13 MODIFY Arg1:T22 Arg2:E13    
49
T23 Distance 482 486    5-cm
50
R14 MODIFY Arg1:T23 Arg2:E13    
51
T24 Detailed_description 517 550    comprised of three septate ulcers
52
R15 MODIFY Arg1:T24 Arg2:E13    
53
T25 Biological_structure 551 597    in the greater curvature of the gastric antrum
54
R16 MODIFY Arg1:T25 Arg2:E13    
55
T26 Diagnostic_procedure 601 625    pathological examination
56
E14 Diagnostic_procedure:T26 
57
T27 Biological_structure 629 654    endoscopic biopsy tissues
58
T28 Disease_disorder 715 729    adenocarcinoma
59
E15 Disease_disorder:T28 
60
T29 Detailed_description 707 714    tubular
61
R17 MODIFY Arg1:T29 Arg2:E15    
62
T30 Detailed_description 681 706    moderately differentiated
63
R18 MODIFY Arg1:T30 Arg2:E15    
64
R19 MODIFY Arg1:T27 Arg2:E14    
65
R20 MODIFY Arg1:E15 Arg2:E14    
66
T31 Diagnostic_procedure 757 776    computed tomography
67
E16 Diagnostic_procedure:T31 
68
T32 Biological_structure 742 756    abdominopelvic
69
R21 MODIFY Arg1:T32 Arg2:E16    
70
T33 Sign_symptom 798 802    mass
71
E17 Sign_symptom:T33 
72
T34 Biological_structure 790 797    gastric
73
R22 MODIFY Arg1:T34 Arg2:E17    
74
R23 MODIFY Arg1:E17 Arg2:E16    
75
T35 Detailed_description 803 823    with deep ulceration
76
R24 MODIFY Arg1:T35 Arg2:E17    
77
T36 Biological_structure 824 845    in the gastric antrum
78
R25 MODIFY Arg1:T36 Arg2:E17    
79
T37 Detailed_description 846 885    with perigastric lymph node enlargement
80
R26 MODIFY Arg1:T37 Arg2:E17    
81
T38 Sign_symptom 890 908    metastatic lesions
82
E18 Sign_symptom:T38 
83
A1  POLARITY E18 NEG
84
T39 Biological_structure 930 935    liver
85
T40 Biological_structure 937 941    lung
86
T41 Biological_structure 945 955    peritoneum
87
R27 MODIFY Arg1:T39 Arg2:E18    
88
R28 MODIFY Arg1:T40 Arg2:E18    
89
R29 MODIFY Arg1:T41 Arg2:E18    
90
T42 Biological_structure 961 966    chest
91
T43 Diagnostic_procedure 967 978    radiography
92
E19 Diagnostic_procedure:T43 
93
R30 MODIFY Arg1:T42 Arg2:E19    
94
T44 Sign_symptom 986 1009   no significant findings
95
E20 Sign_symptom:T44 
96
R31 MODIFY Arg1:E20 Arg2:E19    
97
T45 Therapeutic_procedure 1028 1039 gastrectomy
98
E21 Therapeutic_procedure:T45 
99
T46 Detailed_description 1011 1018  Radical
100
T47 Detailed_description 1019 1027  subtotal
101
R32 MODIFY Arg1:T47 Arg2:E21    
102
R33 MODIFY Arg1:T46 Arg2:E21    
103
T48 Biological_structure 1045 1058  D2 lymph node
104
T49 Therapeutic_procedure 1059 1069 dissection
105
E22 Therapeutic_procedure:T49 
106
T50 Therapeutic_procedure 1086 1103 gastrojejunostomy
107
E23 Therapeutic_procedure:T50 
108
T51 Detailed_description 1074 1085  Billroth II
109
R34 MODIFY Arg1:T48 Arg2:E22    
110
R35 MODIFY Arg1:T51 Arg2:E23    
111
R36 SUB_PROCEDURE Arg1:E22 Arg2:E21 
112
R37 SUB_PROCEDURE Arg1:E23 Arg2:E21 
113
T52 Therapeutic_procedure 2366 2386 postoperative course
114
E24 Therapeutic_procedure:T52 
115
T53 Lab_value 2355 2365 uneventful
116
R38 MODIFY Arg1:T53 Arg2:E24    
117
T54 Clinical_event 2395 2405    discharged
118
E25 Clinical_event:T54 
119
T55 Date 2409 2428  postoperative day 9
120
E26 Date:T55 
121
T56 Date 2430 2445  Two weeks later
122
E27 Date:T56 
123
T57 Diagnostic_procedure 2451 2460  HCG level
124
E28 Diagnostic_procedure:T57 
125
T58 Lab_value 2465 2475 176 mIU/mL
126
R39 MODIFY Arg1:T58 Arg2:E28    
127
T59 Diagnostic_procedure 2512 2521  AFP level
128
E29 Diagnostic_procedure:T59 
129
T60 Lab_value 2526 2536 10.0 ng/mL
130
R40 MODIFY Arg1:T60 Arg2:E29    
131
T61 Medication 2552 2573    adjuvant chemotherapy
132
E30 Medication:T61 
133
T62 Medication 2579 2591    capecitabine
134
E31 Medication:T62 
135
R41 MODIFY Arg1:E31 Arg2:E30    
136
T63 Frequency 2538 2548 Six cycles
137
R42 MODIFY Arg1:T63 Arg2:E30    
138
T64 Dosage 2657 2690    2500 mg/m2 per day for 14 d/cycle
139
R43 MODIFY Arg1:T64 Arg2:E31    
140
T65 Date 2692 2708  After two cycles
141
E32 Date:T65 
142
T66 Diagnostic_procedure 2714 2725  β-HCG level
143
E33 Diagnostic_procedure:T66 
144
T67 Lab_value 2742 2752 < 3 mIU/mL
145
R44 MODIFY Arg1:T67 Arg2:E33    
146
T68 Sign_symptom 2795 2805  recurrence
147
E34 Sign_symptom:T68 
148
T69 Sign_symptom 2809 2827  distant metastasis
149
E35 Sign_symptom:T69 
150
T70 Date 2848 2854  4-year
151
E36 Date:T70 
152
T71 Clinical_event 2855 2878    postoperative follow-up
153
E37 Clinical_event:T71 
154
T72 Biological_structure 1133 1150  resected specimen
155
T73 Sign_symptom 1168 1175  lesions
156
E38 Sign_symptom:T73 
157
T74 Lab_value 1161 1167 double
158
R45 MODIFY Arg1:T74 Arg2:E38    
159
T75 Detailed_description 1191 1243  a 5.8 cm × 3.2 cm ulcerofungating mass in the antrum
160
T76 Detailed_description 1250 1270  extensive hemorrhage
161
R46 MODIFY Arg1:T75 Arg2:E38    
162
R47 MODIFY Arg1:T76 Arg2:E38    
163
T77 Detailed_description 1286 1294  fibrosis
164
R48 MODIFY Arg1:T77 Arg2:E38    
165
T78 Color 1275 1285 light gray
166
R49 MODIFY Arg1:T78 Arg2:T77    
167
T79 Detailed_description 1315 1357  a nearby 2.5 cm × 2.0 cm ulcerative lesion
168
R50 MODIFY Arg1:T79 Arg2:E38    
169
T80 Sign_symptom 1428 1439  tumor cells
170
E39 Sign_symptom:T80 
171
T81 Detailed_description 1420 1427  bizarre
172
T82 Detailed_description 1407 1418  pleomorphic
173
T83 Lab_value 1388 1403 massive numbers
174
R51 MODIFY Arg1:T83 Arg2:E39    
175
R52 MODIFY Arg1:T81 Arg2:E39    
176
R53 MODIFY Arg1:T82 Arg2:E39    
177
T84 Detailed_description 1445 1499  hemorrhage (syncytiotrophoblasts and cytotrophoblasts)
178
R54 MODIFY Arg1:T84 Arg2:E39    
179
T85 Diagnostic_procedure 1535 1577  Hematoxylin and eosin (HE)-stained tissues
180
E40 Diagnostic_procedure:T85 
181
T86 Biological_structure 1603 1612  cytoplasm
182
T87 Color 1596 1602 purple
183
T88 Shape 1589 1595 bubbly
184
R55 MODIFY Arg1:T87 Arg2:T86    
185
R56 MODIFY Arg1:T88 Arg2:T86    
186
T89 Biological_structure 1623 1629  nuclei
187
T90 Detailed_description 1635 1656  magnification of 40 ×
188
T91 Detailed_description 1674 1679  100 ×
189
R57 MODIFY Arg1:T90 Arg2:E40    
190
R58 MODIFY Arg1:T91 Arg2:E40    
191
R59 MODIFY Arg1:T86 Arg2:E40    
192
R60 MODIFY Arg1:T89 Arg2:E40    
193
T92 Lab_value 1617 1622 giant
194
R61 MODIFY Arg1:T92 Arg2:T89    
195
T93 Coreference 1698 1703   tumor
196
E41 Coreference:T93 
197
R62 IDENTICAL Arg1:E41 Arg2:E39 
198
T94 Biological_structure 1717 1742  proper muscle layer (T2a)
199
R63 MODIFY Arg1:T94 Arg2:E41    
200
T95 Sign_symptom 1747 1757  metastasis
201
E42 Sign_symptom:T95 
202
T96 Biological_structure 1768 1802  in four of 56 regional lymph nodes
203
R64 MODIFY Arg1:T96 Arg2:E42    
204
T97 Diagnostic_procedure 1809 1837  Immunohistochemical staining
205
E43 Diagnostic_procedure:T97 
206
T98 Lab_value 1845 1870 positive immunoreactivity
207
T99 Diagnostic_procedure 1875 1905  β-human chorionic gonadotropin
208
E44 Diagnostic_procedure:T99 
209
T100    Diagnostic_procedure 1950 1953  AFP
210
E45 Diagnostic_procedure:T100 
211
T101    Lab_value 1929 1945 focal positivity
212
R65 MODIFY Arg1:T101 Arg2:E45   
213
R66 MODIFY Arg1:T98 Arg2:E44    
214
R67 SUB_PROCEDURE Arg1:E44 Arg2:E43 
215
R68 SUB_PROCEDURE Arg1:E45 Arg2:E43 
216
T102    Disease_disorder 2017 2032  choriocarcinoma
217
E46 Disease_disorder:T102 
218
T103    Biological_structure 2009 2016  gastric
219
R69 MODIFY Arg1:T103 Arg2:E46   
220
T104    Disease_disorder 2151 2165  adenocarcinoma
221
E47 Disease_disorder:T104 
222
T105    Biological_structure 2143 2150  tubular
223
T106    Disease_disorder 2079 2093  adenocarcinoma
224
E48 Disease_disorder:T106 
225
T107    Detailed_description 2065 2078  AFP-producing
226
R70 MODIFY Arg1:T107 Arg2:E48   
227
R71 MODIFY Arg1:T105 Arg2:E47   
228
T108    Biological_structure 2173 2205  extended to the submucosal layer
229
R72 MODIFY Arg1:T108 Arg2:E47   
230
R73 MODIFY Arg1:T4 Arg2:E1  
231
*   OVERLAP E1 E2 E3
232
R74 AFTER Arg1:E3 Arg2:E5   
233
R75 BEFORE Arg1:E5 Arg2:E6  
234
*   OVERLAP E6 E12 E13 E14 E15
235
R76 BEFORE Arg1:E15 Arg2:E16    
236
*   OVERLAP E16 E17 E18 E19 E20
237
R77 BEFORE Arg1:E20 Arg2:E21    
238
R78 BEFORE Arg1:E21 Arg2:E38    
239
R79 MODIFY Arg1:T72 Arg2:E38    
240
*   OVERLAP E38 E39 E40 E42 E41 E43 E46 E48 E47
241
R80 BEFORE Arg1:E47 Arg2:E24    
242
R81 BEFORE Arg1:E24 Arg2:E25    
243
*   OVERLAP E25 E26
244
R82 BEFORE Arg1:E26 Arg2:E27    
245
*   OVERLAP E27 E28 E29
246
R83 BEFORE Arg1:E29 Arg2:E30    
247
R84 BEFORE Arg1:E30 Arg2:E32    
248
*   OVERLAP E32 E33
249
R85 BEFORE Arg1:E33 Arg2:E34    
250
A2  POLARITY E34 NEG
251
A3  POLARITY E35 NEG
252
*   OVERLAP E34 E35 E36 E37
253
T109    Lab_value 2730 2738 declined
254
E49 Lab_value:T109 
255
R86 MODIFY Arg1:E49 Arg2:E33